National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

monoclonal antibody hLL1
A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Monoclonal antibody hLL1 specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:humanized anti-CD74 monoclonal antibody hLL1
Code name:hLL1



Previous:monoclonal antibody E2.3, monoclonal antibody G250, monoclonal antibody GD2 anti-idiotype vaccine, monoclonal antibody hA20, monoclonal antibody HeFi-1
Next:monoclonal antibody Hu3S193, monoclonal antibody HuAFP31, monoclonal antibody HuHMFG1, monoclonal antibody HuM291, monoclonal antibody HuPAM4

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov